English
French
SAINT LAURENT, QUEBEC-(Marketwire - 08/31/09) – (TSX-V:IGX) (OTC.BB:IGXT) - Horst G. Zerbe, President and CEO of IntelGenx Technologies Corp. ("IntelGenx") will be holding a shareholder conference call to update shareholders on the company’s CPI-300 product and remark on related legal proceedings. The call will be held on Tuesday September 1, 2009 at 2.30 p.m. Eastern Standard Time.
Conference Call
---------------
Date: Tuesday, September 1, 2009
Time: 2:30 p.m. Eastern Standard Time
Local Dial-In Number: 719-457-2629
Toll Free North America: 888-300-2343
Passcode: 4094736
To participate in the call, please dial 888-300-2343 or 719-457-2629 five to ten minutes prior to the 2.30 p.m. start of the teleconference. The passcode for the call will be 4094736. This conference call will be recorded and archived for 30 days, and can be accessed beginning on the business day following the conference call by visiting IntelGenx’s website, at www.intelgenx.com, and clicking on the “Investors” link. A transcript of the call will also be made available on IntelGenx's website at www.intelgenx.com and can be viewed at www.sec.gov under cover of Form 8-K filed on September 1, 2009.
CPI-300:
CPI-300 was formulated using IntelGenx's proprietary controlled release technology. It contains a new strength of a widely prescribed antidepressant. CPI-300 was developed to broaden the dosing options for physicians while providing a more convenient dosing option for patients requiring a higher strength of the products currently available. It will be indicated for the treatment of major depressive disorder.
About IntelGenx Corp.:
IntelGenx Corp. is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. The Company uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastro-intestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. The Company's research and development pipeline includes products for the treatment of pain, hypertension, osteoarthritis, and depressive disorders. More information is available about the Company at http://www.intelgenx.com/.
The TSX and OTCBB have neither approved nor disapproved of the information contained herein.
Contacts:
Dr. Horst G. Zerbe President and CEO
IntelGenx Corp.
(514) 331-7440x201
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Website: www.intelgenx.com